Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients.

It has been demonstrated that prolonged in vivo or in vitro treatment with some nucleosides analogs may favor the selection of cells with a reduced activity of enzymes involved in the phosphorylation of these drugs leading to a reduced sensitivity to their antiretroviral action. The aim of this study was to evaluate the effect, in vivo, of zidovudine and stavudine treatment on thymidine kinase (TK) activity. The results obtained showed that TK levels in PBMC from naive patients and stavudine-treated patients did not significantly differ (naive TK = 4.16 +/- 1.19 U/mg protein; stavudine TK = 3.65 +/- 1.73 U/mg protein; p = 0.42), suggesting that the treatment with this nucleoside analog is not associated to a defect of TK activity. On the contrary, PBMC from zidovudine-treated patients showed a significant reduction in TK activity compared to naive patients (naive TK = 4.16 +/- 1.19 U/mg protein; zidovudine TK = 2.70 +/- 1.54; p = 0.014. Although the clinical significance of these results has to be established, we can speculate that stavudine and zidovudine, which are presumably phosphorylated by the same cellular kinases, might display a different ability to in vivo select cells with a resistant phenotype.

[1]  P. Narciso,et al.  Discordance between Genotypic and Phenotypic Drug Resistance Profiles in Human Immunodeficiency Virus Type 1 Strains Isolated from Peripheral Blood Mononuclear Cells , 2002, Journal of Clinical Microbiology.

[2]  C. Scagnolari,et al.  Selection of a T-Cell Line Resistant to Stavudine and Zidovudine by Prolonged Treatment with Stavudine , 2001, Antiviral therapy.

[3]  C. Loveday,et al.  Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents , 2001, Antimicrobial Agents and Chemotherapy.

[4]  E. Rosenberg,et al.  Antiretroviral resistance during successful therapy of HIV type 1 infection. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W. O'brien,et al.  Resistance against reverse transcriptase inhibitors. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Connelly,et al.  Cellular Factors for Resistance against Antiretroviral Agents , 1999, Antiviral therapy.

[7]  B. Jacobsson,et al.  Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. , 1998, Biochemical pharmacology.

[8]  O. Turriziani,et al.  Anti-HIV Antiviral Activity of Stavudine in a Thymidine Kinase-Deficient Cellular Line , 1998, Antiviral therapy.

[9]  Y. Chiang,et al.  Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes. , 1997, Antiviral research.

[10]  J. Gambertoglio,et al.  Zidovudine phosphorylation after short‐term and long‐term therapy with zidovudine in patients infected with the human immunodeficiency virus , 1996, Clinical pharmacology and therapeutics.

[11]  P. Narciso,et al.  Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. , 1996, AIDS research and human retroviruses.

[12]  G. Th.  The International Retrovirology Association Starts a New Venture with JAIDS & HR of Raven Press , 1995 .

[13]  V. Avramis,et al.  Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. , 1993, Journal of acquired immune deficiency syndromes.

[14]  A. Pesce,et al.  Concentrations of Phosphorylated Zidovudine (ZDV) in Patient Leukocytes Do Not Correlate with ZDV Dose or Plasma Concentrations , 1991, Therapeutic drug monitoring.